Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 4/20 | 0.46 |
| ▸ | HPGDS | O60760 | 1/20 | 0.44 |
| ▸ | LCK | P06239 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.40 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.39 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.39 |
| ▸ | BRD4 | O60885 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.37 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.36 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | HTR2A | P28223 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4231887 | 0.84 | MAPK14 (0.49) | MAPK14KMT2AHDAC1HDAC6RAB9A | |
| SCHEMBL14161063 | 0.84 | MAPK14 (0.43) | MAPK14HPGDSLCKKMT2AHDAC1 | |
| SCHEMBL4035180 | 0.81 | MAPK14 (0.56) | MAPK14HPGDSLCKKMT2AHDAC1 | |
| SCHEMBL2214493 | 0.78 | MAPK14 (0.40) | MAPK14HPGDSLCKKMT2AHDAC1 | |
| SCHEMBL3892152 | 0.76 | HPGDS (0.49) | MAPK14HPGDSLCKKMT2AMAPK8 | |
| SCHEMBL4739276 | 0.75 | MAPK14 (0.46) | MAPK14HPGDSLCKMAPK8MAPK10 | |
| SCHEMBL3767339 | 0.74 | RAB9A (0.51) | MAPK14HPGDSLCKKMT2AHDAC1 | |
| SCHEMBL4225169 | 0.73 | SIRT2 (0.44) | MAPK14HPGDSHDAC1HDAC6 | |
| SCHEMBL4740641 | 0.73 | SMN1; SMN2 (0.54) | MAPK14LCKKMT2APOLBRAB9A | |
| SCHEMBL396727 | 0.72 | POLB (0.53) | MAPK14HPGDSKMT2AMAPK8MAPK10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1709046-B1 | P38 KINASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2011-07-27 | — | — | EP | disclosed |
| EP-1709046-B1 | P38 KINASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2011-07-27 | — | — | EP | disclosed |
| US-20090023725-A1 | Fused Heteroaryl Derivatives for Use as P38 Kinase Inhibitors | SMITHKLINE BEECHAM CORPORATION | 2009-01-22 | — | — | US | disclosed |
| US-20090023725-A1 | Fused Heteroaryl Derivatives for Use as P38 Kinase Inhibitors | SMITHKLINE BEECHAM CORPORATION | 2009-01-22 | — | — | US | disclosed |
| US-20090023725-A1 | Fused Heteroaryl Derivatives for Use as P38 Kinase Inhibitors | SMITHKLINE BEECHAM CORPORATION | 2009-01-22 | — | — | US | disclosed |
| EP-1708996-B1 | FUSED HETEROYRAL DERIVATIVES FOR USE AS P38 KINASE INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2008-08-27 | — | — | EP | disclosed |
| EP-1708996-B1 | FUSED HETEROYRAL DERIVATIVES FOR USE AS P38 KINASE INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2008-08-27 | — | — | EP | disclosed |
| WO-2008071665-A1 | A NICOTINAMIDE DERIVATIVE USEFUL AS P38 KINASE INHIBITOR | SMITHKLINE BEECHAM CORPORATION (US) | 2008-06-19 | — | — | WO | disclosed |
| WO-2008071664-A1 | NICOTINAMIDE DERIVATIVE USED AS A P38 KINASE INHIBITOR | SMITHKLINE BEECHAM CORPORATION (US) | 2008-06-19 | — | — | WO | disclosed |
| WO-2008071664-A1 | NICOTINAMIDE DERIVATIVE USED AS A P38 KINASE INHIBITOR | SMITHKLINE BEECHAM CORPORATION (US) | 2008-06-19 | — | — | WO | disclosed |
| WO-2008071665-A1 | A NICOTINAMIDE DERIVATIVE USEFUL AS P38 KINASE INHIBITOR | SMITHKLINE BEECHAM CORPORATION (US) | 2008-06-19 | — | — | WO | disclosed |
| US-20070161673-A1 | P38 kinase inhibitors | SMITHKLINE BEECHAM CORPORATION | 2007-07-12 | — | — | US | disclosed |
| US-20070161673-A1 | P38 kinase inhibitors | SMITHKLINE BEECHAM CORPORATION | 2007-07-12 | — | — | US | disclosed |
| US-20070161673-A1 | P38 kinase inhibitors | SMITHKLINE BEECHAM CORPORATION | 2007-07-12 | — | — | US | disclosed |
| EP-1708996-A1 | FUSED HETEROYRAL DERIVATIVES FOR USE AS P38 KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2006-10-11 | — | — | EP | disclosed |
| WO-2005073189-A1 | FUSED HETEROYRAL DERIVATIVES FOR USE AS P38 KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-08-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090023725-A1 | Fused Heteroaryl Derivatives for Use as P38 Kinase Inhibitors | MAPK1, MAPKAPK2, MAPK7 | MAPK14 19/4885HPGDS 122/4885LCK 131/4885 |
| US-20070161673-A1 | P38 kinase inhibitors | MAPK1, MAPK7, MAP3K1 | MAPK14 14/4885HPGDS 118/4885LCK 94/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.